Rh blood group D antigenGenealiases: CD240D · DIIIc · HDFNRH · RH · RH30 · RHCED
Q-omics provides the consensus-scored RHD profile across patient tissues and cancer cell-line models. RHD expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, RHD is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, RHD RNA expression shows 15,951 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight READ, BRCA, and DLBC as cancer lineages where RHD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHD survival associations across molecular data types. RHD RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHD RNA expression–survival associations across cancer types. High RHD expression shows unfavorable associations in LUSC, ACC and KIRP, but favorable associations in READ, PAAD and LUAD. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify READ as the clearest survival context for RHD RNA expression.
This table summarizes RHD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RHD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHD shows lower tumor expression in BRCA, UCEC and KICH and higher tumor expression in KIRC, LIHC and BLCA. The BRCA box plot shows higher RHD RNA expression in normal versus tumor tissue (log2 FC = −0.364, t-test p < 0.001).
This table shows molecular features associated with RHD in patient tissues and cancer cell lines. In patient samples, RHD shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
